IBSA USA
Josh Posner is a highly accomplished sales professional currently serving as a Specialty Sales Representative III at IBSA USA since May 2022, where notable achievements include being the 2023 Veloce Award Winner and achieving a 940% growth in Licart tRx. Ranked #4 overall in the US in 2023, Josh also excelled as the #1 sales representative for Licart Rx in Q1 FY’23 and maintained a top 10 overall ranking for Q1, Q2, and Q3 FY’23. Previously, Josh worked at Tactile Medical as an Associate Product Specialist, earning the 2021 Quota Breaker Award and contributing to the District of the Year recognition. At ADP, Josh gained experience in outside sales for small business services. Josh holds a Bachelor of Science in Marketing from the University of Delaware.
This person is not in any teams
IBSA USA
IBSA USA is the subsidiary of IBSA Group, the largest privately owned pharmaceutical company in Switzerland. IBSA is committed to improving patient quality of life through research, innovation, and the development of effective drugs and cutting-edge technologies. IBSA USA markets two unique levothyroxine formulations in the U.S. for the treatment of hypothyroidism: Tirosint® (levothyroxine sodium) capsules and Tirosint®-SOL (levothyroxine sodium) oral solution. IBSA also markets Licart™ (diclofenac epolamine) topical system 1.3%, the only once-a-day topical nonsteroidal anti-inflammatory (NSAID) available in the U.S. to treat acute pain due to minor strains, sprains, and contusions. IBSA is focused on the health and well-being of patients and driven by the desire to bring therapeutic alternatives to as many people as possible. IBSA Group bases its philosophy on four sustainable pillars: Person, Innovation, Quality, and Responsibility. For more information about Tirosint, Tirosint-SOL, or Licart, including Full Prescribing Information, go to each brand’s respective website.